News | November 08, 2013

Largest Ever Study of Male Breast Cancer Treatment Shows More Mastectomy, Less Radiation Than in Female Disease

November 8, 2013 — University of Colorado Cancer Center researchers used data from 4,276 cases of male breast cancer and 718,587 cases of female breast cancer to show that the disease is treated differently in men than in women. Specifically, male breast cancer is treated with mastectomy more often than female breast cancer, and in cases in which locally advanced female breast cancer is commonly treated with radiation, the treatment is less used in the male disease. Results are published in this month's issue of the International Journal of Radiation Oncology, Biology and Physics.

"We know very little about male breast cancer since it comprises only 0.6 percent of all breast cancer, and nearly all therapy is based on female breast cancer studies. This study demonstrates that just as in women, men with early stage breast cancer have the same outcome with a mastectomy or a lumpectomy followed by radiation. In women, breast-conserving surgery is the standard and preferred treatment for the majority of women. Still, 87 percent of men in this study, compared to only 38 percent of women during the same time period, underwent mastectomy for early stage disease," says Rachel Rabinovitch, M.D., investigator at the CU Cancer Center and professor of Radiation Oncology at the University of Colorado School of Medicine.

"Traditionally, breast conservation is not even considered for men with breast cancer. But in a world in which a man's appearance is increasingly important, and where it is common for men to be seen without a shirt in the gym or on the beach, mastectomy can have overlooked psycho-sexual impacts on men, just as in women," Rabinovitch says.

The group's data comes from the U.S. Surveillance, Epidemiology and End Results (SEER) Program database, which has collected cancer statistics since 1973 and includes tumor type, demographics, treatment and outcome information for about 28 percent of the U.S. population.

"Because male breast cancer is a rare disease, it isn’t studied prospectively – it is very challenging to enroll enough patients in a trial evaluating therapy for male breast cancer. To learn about the disease from large patient groups, we have to look back through collected data, like that in SEER. So the question becomes what can you learn from these numbers? What can you find that's useful, practical, new and interesting?" Rabinovitch says.

The study also shows that whereas mastectomy may be over-used in male breast cancer, radiation therapy may be under-utilized. In locally advanced breast cancer the disease is comprised of a large tumor mass or has spread to the surrounding chest wall, nearby skin or underarm lymph nodes but not yet to other organs. In the current study, 34 percent of males with locally advanced disease were treated with radiation therapy following mastectomy, compared with 45 percent of females with similar disease.

"I think these findings point to new areas of research and should push clinicians to consider the advantages of breast conserving therapy with their patients. It's a new conversation – surgeons and oncologists shouldn't assume that men are fine with a mastectomy," Rabinovitch says.

For more information: www.ucdenver.edu/academics/colleges/medicalschool/centers/cancercenter/P...

Related Content

ProCure Proton Therapy Center New Jersey Celebrates Five-Year Cancer-Free Milestone for Prostate Cancer Patients
News | Proton Therapy | September 20, 2017
ProCure Proton Therapy Center in Somerset, N.J., recently celebrated the five-year cancer-free milestone for the first...
Varian to Showcase Latest Radiation Therapy Technologies and Software at ASTRO 2017
News | Radiation Therapy | September 19, 2017
Varian Medical Systems announced it will be demonstrating its new Halcyon platform and HyperArc high-definition...
Elekta to Highlight MOSAIQ Oncology Analytics at ASTRO Annual Meeting
News | Radiation Therapy | September 19, 2017
September 19, 2017 — Elekta will highlight its Mosaiq Oncology...
Theraclion to Launch Metastatic Breast Cancer Trial Combining Echotherapy and Immunotherapy
News | Focused Ultrasound Therapy | September 18, 2017
September 18, 2017 — Theraclion and co-lead investigator David Brenin, M.D., from the University of Virginia School o
Double Targeting Ligands to Identify and Treat Prostate Cancer

The mice were imaged with small-animal PET/CT using 124I-RPS-027 (7.4 MBq [200 μCi]). Credit: JM Kelly et al., Department of Radiology, Weill Cornell Medicine, New York, NY

News | Prostate Cancer | September 14, 2017
Researchers have demonstrated a new, effective way to precisely identify and localize prostate cancer tumors while...
Clinical Trials and Cutting-Edge Radiation Oncology Research to Be Featured at ASTRO 2017
News | Radiation Therapy | September 14, 2017
The program for the 2017 Annual Meeting of the American Society for Radiation Oncology (ASTRO), Sept. 24-27 in San...
Blue Earth Diagnostics Announcing Results of FALCON PET/CT Trial at ASTRO 2017
News | PET-CT | September 13, 2017
September 13, 2017 — Blue Earth Diagnostics announced the upcoming oral presentation of initial results from the FALC
DenseBreast-info.org Debuts  Spanish Language Video  About Dense Breasts
News | Breast Density | September 12, 2017
Breast cancer risks associated with breast density are the subject of a new Spanish language video launched recently by...
Asian Study Underlines Potential Value of Pressure-Guided Mammography
News | Mammography | September 11, 2017
Sigmascreening recently announced that a study of in total 15,898 in digital mammograms from 3,772 Asian women...
Overlay Init